Pembrolizumab for early triple-negative breast cancer
Pembrolizumab for early triple-negative breast cancer
Pembrolizumab is an immune checkpoint inhibitor (ICPI), a type of immunotherapy that blocks the programmed death 1 (PD1) receptor expressed on T cells. In cancer, PD1 binds to its ligand, programmed death ligand 1 (PDL1), which is expressed by both innate immune cells and tumour cells and prevents T cells from killing cancer cells. Triple-negative breast cancer (TNBC) is characterised by a higher density of immune cell infiltrates, a higher expression of PDL1 and a higher tumour mutational burden than other breast cancer subtypes, making ICPI a promising treatment option in TNBC. 1 Furthermore, the use of anthracyclines, taxanes and platinum-based neoadjuvant chemotherapy is associated not only with improved pathological complete responses (pCRs) but also with increased PDL1 expression in tumour cells in TNBC. 2 The KEYNOTE-522 study investigated whether the combination of chemotherapy and ICPI improves clinical outcomes in this group of patients.
205-210
Savva, Constantinos
d6e87674-1443-41f4-84ba-81c1ccfeb3d7
Copson, Ellen
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
1 January 2024
Savva, Constantinos
d6e87674-1443-41f4-84ba-81c1ccfeb3d7
Copson, Ellen
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Savva, Constantinos and Copson, Ellen
(2024)
Pembrolizumab for early triple-negative breast cancer.
In,
Wyld, Lynda, Cutress, Ramsey and Morgan, Jenna
(eds.)
50 Landmark Papers: Every Breast Surgeon Should Know.
CRC Press, .
(doi:10.1201/b23352-37).
Record type:
Book Section
Abstract
Pembrolizumab is an immune checkpoint inhibitor (ICPI), a type of immunotherapy that blocks the programmed death 1 (PD1) receptor expressed on T cells. In cancer, PD1 binds to its ligand, programmed death ligand 1 (PDL1), which is expressed by both innate immune cells and tumour cells and prevents T cells from killing cancer cells. Triple-negative breast cancer (TNBC) is characterised by a higher density of immune cell infiltrates, a higher expression of PDL1 and a higher tumour mutational burden than other breast cancer subtypes, making ICPI a promising treatment option in TNBC. 1 Furthermore, the use of anthracyclines, taxanes and platinum-based neoadjuvant chemotherapy is associated not only with improved pathological complete responses (pCRs) but also with increased PDL1 expression in tumour cells in TNBC. 2 The KEYNOTE-522 study investigated whether the combination of chemotherapy and ICPI improves clinical outcomes in this group of patients.
This record has no associated files available for download.
More information
Published date: 1 January 2024
Additional Information:
Publisher Copyright:
© 2024 selection and editorial matter, Lynda Wyld, Ramsey Cutress and Jenna Morgan; individual chapters, the contributors.
Identifiers
Local EPrints ID: 490763
URI: http://eprints.soton.ac.uk/id/eprint/490763
PURE UUID: 10723c14-3960-4170-b162-40a2ac645369
Catalogue record
Date deposited: 06 Jun 2024 16:37
Last modified: 25 Jul 2024 01:55
Export record
Altmetrics
Contributors
Editor:
Lynda Wyld
Editor:
Ramsey Cutress
Editor:
Jenna Morgan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
